ACUTE REPETITIVE SEIZURES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global acute repetitive seizures market is estimated to be valued at USD 3.10 Bn in 2024, and is expected to exhibit a CAGR of 12.6%  during the forecast period (2024-2031). Acute repetitive seizures (ARS) are characterized by two or more unprovoked seizures occurring within a 24-hour period without restoration of consciousness between the seizures. Acute repetitive seizures contributes significantly to the disease burden among epileptic patients. Factors  contributing to increase in ARS cases globally includes growing geriatric population prone to seizures and increasing prevalence of epilepsies arising from strokes, brain injuries, and neuroinfectious. However, advancements in ARS treatment options such as newer generation anticonvulsants and dedicated emergency treatment protocols in hospitals are expected to aid patients and drive the market growth in the near future.

Market Dynamics:

Global acute repetitive seizures market growth is p driven by increasing incidence of epilepsy worldwide. It is estimated that 50 million people suffer from epilepsy globally. Furthermore, rising geriatric population susceptible to neurological disorders, strokes, and brain injuries leading to seizures boosts demand for acute repetitive seizures treatment over the forecast period. However, high costs of emergency care and unmet medical needs in low-income regions can hamper the market growth. Development of inexpensive generic anticonvulsants provides opportunities for  the market growth. Initiatives aimed at raising awareness about timely identification and treatment of ARS can reduce mortality and disability rates.

Key Features of the Study:

• This report provides an in-depth analysis of the global acute repetitive seizures market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global acute repetitive seizures market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Neurelis, Inc., Bausch Health Companies Inc., Alexza Pharmaceuticals, Inc., VERITON PHARMA, UCB S.A., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi, GSK plc, Eisai Co., Ltd., H. Lundbeck A/S, Cognizance Biomarkers, LLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global acute repetitive seizures market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute repetitive seizures market.

Detailed Segmentation-

• By Drug Type:
  • Benzodiazepines
  • Antiepileptic drugs
  • Barbiturates
  • Others (Late Phase Drugs, etc.)
• By Route of Administration:
  • Oral
  • Injectable
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Company Profiles:

• Neurelis, Inc.
• Bausch Health Companies Inc.
• Alexza Pharmaceuticals, Inc.
• VERITON PHARMA
• UCB S.A.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Sanofi
• GSK plc
• Eisai Co., Ltd.
• Lundbeck A/S
• Cognizance Biomarkers, LLC